For research use only
| Cat No. | ABC-TC3947 |
| Product Type | Immune Cells |
| Cell Type | Mononuclear Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Multiple Myeloma |
| Storage | Liquid Nitrogen |
Leverage Human Multiple Myeloma Bone Marrow Mononuclear Cells (Relapsed/Refractory) for drug resistance analysis, immune profiling, and tumor progression.
Human Multiple Myeloma Bone Marrow Mononuclear Cells (Relapsed/Refractory) are primary cells isolated from the bone marrow of donors with relapsed or refractory multiple myeloma. These cells are non-passaged and exhibit a mixed morphology with atypical plasma cells and mononuclear subsets in suspension. Functionally, these human bone marrow cells display characteristic in vitro profiles associated with multidrug resistance, anti-apoptotic signaling, and microenvironment-related cell survival. The cells express CD38. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | Human Multiple Myeloma Bone Marrow Mononuclear Cells (Relapsed/Refractory), MM BM-MNCs, Relapsed Multiple Myeloma BM MNCs, Refractory Myeloma Bone Marrow Cells |
| Species | Human |
| Cat.No | ABC-TC3947 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Multiple Myeloma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Immune Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Multiple Myeloma Bone Marrow Mononuclear Cells (Relapsed/Refractory) serve as an in vitro model to study disease-associated drug resistance profiles and underlying molecular mechanisms. For instance, analyzing their survival under chemotherapy, drug efflux pump expression, and altered signaling pathways helps explore molecular drivers of treatment resistance, supporting discovery research and target identification for myeloma drug resistance.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).